A Phase 1/1b Open-Label Dose Escalation and Expansion Study of Bcl-2 Inhibitor BGB-11417 in Patients with Mature B-Cell Malignancies
Study of BGB-11417 in Patients with Leukemia
Sponsor: BeiGene, Ltd
Enrolling: Male and Female Patients
IRB Number: AAAT5414
U.S. Govt. ID: NCT04277637
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is to look at the safety and tolerability of an investigational anticancer drug currently known as BGB-11417. This study aims to determine the range of BGB-11417 doses that can safely be used, the safest dosing schedule to minimize side effects when first taking BGB-11417, what side effects may be experienced when taking this drug, how your body processes this drug, and if this drug is effective against your cancer.
Nicole Lamanna, MD
Do You Qualify?
Are you at least 18 years old? Yes No
Have you been diagnosed with leukemia? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator